GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » 5-Year Yield-on-Cost %

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings 5-Year Yield-on-Cost %?

Parnell Pharmaceuticals Holdings's yield on cost for the quarter that ended in Dec. 2018 was 0.00.


The historical rank and industry rank for Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



PARNF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.22
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost % falls into.



Parnell Pharmaceuticals Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Parnell Pharmaceuticals Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Parnell Pharmaceuticals Holdings 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.